Elevai Labs (NASDAQ:ELAB) and Inventiva (NASDAQ:IVA) Head to Head Analysis

Elevai Labs (NASDAQ:ELAB) and Inventiva (NASDAQ:IVA) are both small-cap multi-sector conglomerates companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 1.3% of Elevai Labs shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Elevai Labs and Inventiva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elevai Labs	-223.41%	-124.93%	-85.10%
Inventiva	N/A	N/A	N/A

Earnings & Valuation

This table compares Elevai Labs and Inventiva”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevai Labs	$2.45 million	1.52	-$4.30 million	($62.00)	-0.02
Inventiva	$15.62 million	10.35	-$119.51 million	N/A	N/A

Elevai Labs has higher earnings, but lower revenue than Inventiva.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Elevai Labs and Inventiva, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevai Labs	0	0	0	0	0.00
Inventiva	0	1	4	0	2.80

Inventiva has a consensus price target of $12.60, indicating a potential upside of 309.09%. Given Inventiva’s stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Elevai Labs.

Risk and Volatility

Elevai Labs has a beta of -3.28, meaning that its share price is 428% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Summary

Inventiva beats Elevai Labs on 10 of the 12 factors compared between the two stocks.

About Elevai Labs

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.